The size of the Vaccine Adjuvant Market in the Asia Pacific is predicted to be growing at a CAGR of 11.73% from 2022 to 2027. As a result, the market size is forecasted to grow USD 203 million by 2027 from USD 116.5 million in 2022.
Vaccine adjuvants are desirable to expand the adaptive immune reactions to antigens. Adjuvants show their effects through diverse mechanisms. Some adjuvants work as delivery systems that provide stimulation of the immune system. Immunologic adjuvants are added to vaccines for the stimulus of the immune system's reaction to the target antigen but directly do not offer immunity. Adjuvants may act in several ways to present an antigen in the immune system. Adjuvants may also serve as the annoyance to involve and intensify the body's immune response.
Factors driving the world vaccine adjuvants market are increasing government funding in R&D, the high occurrence of diseases, the growing emphasis on improved vaccines, and progressive strategic moves assumed by companies such as contracts, acquisitions, and associations.
However, the side effects of adjuvants and the cost of adjuvant growth restrict the market growth.
This research report on the APAC vaccine adjuvant market has been segmented and sub-segmented into the following categories:
By Type:
By Route Of Administration:
By Mechanism Of Action:
By Country:
Regionally, China, and India, being developing countries with an increase in population, are estimated to grow at the highest CAGR in the forecast period.
The Indian vaccine adjuvant market accounted for the largest share in the Asia Pacific market in 2020. The World health organization (WHO) estimated that there are 15 million malaria cases, with 19000-20000 deaths every year in India. In 2020, the collaboration between Novavax and the serum institute of India had introduced a next-generation commercial vaccine adjuvant to treat infectious diseases. Therefore, it helps to boost the Indian vaccine adjuvant market. Recently, the Indian government developing its drug discovery and innovation in vaccine adjuvant with collaboration with the US research center is driving the growth of the Indian vaccine adjuvant market.
In China, Biodegradable nanomaterial and nanotechnology have played a crucial role in developing vaccine adjuvants due to their application, such as better immune effect, less toxic, and dose accuracy, driving the growth of the Chinese population vaccine adjuvant market. Also, rising coronavirus patients in china and development in healthcare industries like CpG 1018 product offering to boost immune response in China is fuelling the market's growth. In addition, China has the most massive burden of Hepatitis-B disease. Nearly 70 million people infected by this disease in 2018 are propelling the growth of the vaccine adjuvants market in China.
The new vaccine and adjuvant center were established in Japan to develop an immune response against disease and other diseases such as Alzheimer’s, hypertension, and epilepsy. As a result, the Japanese vaccine adjuvants market is estimated to project a healthy CAGR during the forecast period.
KEY MARKET PLAYERS:
Companies playing a leading role in the APAC vaccine adjuvant market profiled in this report are MPV Technologies, Avanti Polar Lipids, Novavax Inc. Brenntag Biosector, SEPPIC, Agenus, Inc., Invivogen, SPI Pharma, Inc., CSL Limited, and OZ Biosciences.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Type
5.1.1 Aluminium Salts
5.1.2 Tensoactive Adjuvants
5.1.3 Adjuvant Emulsions
5.1.4 Bacteria derived Adjuvants
5.1.5 Liposome Adjuvants
5.1.6 Carbohydrate Adjuvants
5.2 By Route of Administration
5.2.1 Oral
5.2.2 Intradermal
5.2.3 Subcutaneous
5.2.4 Intranasal
5.2.5 Intramuscular
5.3 By Mechanism of Action
5.3.1 Immuno Stimulants
5.3.2 Carriers
5.3.3 Vehicle Adjuvants
6. Geographical Analysis
6.3 Asia-Pacific
6.1 Introduction
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
6.6 Australia
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 MPV Technologies
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Avanti Polar Lipids
8.3 Novavax Inc.
8.4 Brenntag Biosector
8.5 SEPPIC
8.6 Agenus, Inc.
8.7 Invivogen
8.8 SPI Pharma Inc.
8.9 CSL Limited
8.10 OZ Biosciences
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Expert Opinions
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Talk to our analyst and get customised report done according to your research needs
Check if you can avail any discount. Submit your details and our team will get back to you.
Request to avail a free sample report that reflects this market and its growth.
